---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-211904"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:49:37.639072+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# 4DMT Q1 net loss $68.8M; cash $458M; 4D-150 Phase 3 enrollment complete

## Summary
- Cash $458M as of Mar 31, 2026, down from $514M; expected to fund ops into H2 2028.
- Net loss $68.8M vs $48.0M YoY; R&D expenses rose to $65.0M on Phase 3 trial execution.
- 4D-150 wet AMD Phase 3 (4FRONT-1) randomization complete (N=523); topline data H1 2027.
- PRISM Phase 2b 2-year data for wet AMD expected at a conference Q3 2026; SPECTRA DME 2-year data H2 2026.
- 4D-710 (CF) AEROW trial update expected H2 2026; 4D-175 (GA) evaluating strategic funding.

## SEC filing metadata
- accession: 0001193125-26-211904
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312526211904/0001193125-26-211904-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312526211904/fdmt-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-211904
- JSON: https://secwatch.observer/filing/0001193125-26-211904.json
- Plain text: https://secwatch.observer/filing/0001193125-26-211904.txt

## Source-grounded claims
- claim_id: 4b9be7769ed31ff1ac7422dbc790ab566223fa7c
  claim: 4D Molecular Therapeutics, Inc. reported the three months ended March 31, 2026 results: revenue $3.0 million, net income Net loss was $68.8 million.
  evidence_excerpt: fund our operating expenses and capital expenditure requirements at least into the second half of 2028. Collaboration and License Revenue : Collaboration and license revenue was $3.0 million for the first quarter of 2026, as compared to an insignificant amount for the first quarter of 2025. The increase in revenue was primarily due to the clinical trial cost sharing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650648/000119312526211904/0001193125-26-211904-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.